Core Viewpoint - Dexcom experienced a challenging year in 2024, with shares down 19% over the trailing-12-month period, but there are compelling reasons to consider investing in the company [1] Group 1: Challenges Faced - Dexcom faced regulatory scrutiny and customer complaints due to defects in some continuous glucose monitoring (CGM) receivers, leading to a Class 1 recall of 602,445 G7 receivers [2] - The recall was precautionary, and many patients opted to use a mobile app instead of the receiver, indicating that demand for Dexcom's products remains strong despite the issues [3] Group 2: Financial Performance - In Q3 2024, Dexcom's revenue grew by 22% year over year to $1.2 billion, with adjusted earnings per share increasing by 35.6% to $0.61 compared to the previous year [4] - The company ended 2024 with approximately 2.8 million to 2.9 million customers, a number likely to have increased in 2025, with only 112 complaints received regarding the defective receivers [4] Group 3: Growth Potential - Dexcom is a leader in the CGM market and has significant growth opportunities, particularly among patients with type 1 diabetes and those with type 2 diabetes on intensive insulin therapy, which have historically been the primary target markets [5] - There remains a large addressable market within the core U.S. market, indicating potential for further expansion [5]

Core Viewpoint - DexCom's stock has declined by 25% since the beginning of 2025, despite a generally positive stock market environment, raising questions about its future performance and potential buying opportunities [1][2]. Financial Performance - DexCom reported third-quarter earnings on October 30, with revenue of $1.2 billion, reflecting a year-over-year increase of 22%. However, this growth is compared to a period of slow growth last year, leading to skepticism among investors regarding its sustainability [4]. Market Concerns - Investors are increasingly bearish on DexCom due to the emergence of GLP-1 weight loss drugs, which may reduce the demand for continuous glucose monitoring (CGM) devices. These drugs have shown effectiveness in lowering glucose levels for diabetes patients, potentially impacting DexCom's market [5][6]. Stock Valuation - DexCom's stock is currently trading at levels not seen since the COVID-19 crash of 2020, with a forward price-to-earnings (P/E) multiple of 26, which is lower than its historical average. This situation may present a buying opportunity for investors [7][8].

Group 1: Company Overview - DexCom, Inc. is a leading provider of continuous glucose monitoring (CGM) devices, serving millions of individuals managing Type 1 and Type 2 diabetes, as well as those tracking glucose for wellness purposes [2] - Founded in 1999, DexCom pioneered accurate, real-time glucose monitoring, shifting the standard of care away from periodic finger pricks [2] - The company's competitive edge lies in product performance and integration across platforms, with devices like G6, G7, and Stelo offering seamless connectivity compared to competitors [2] Group 2: Business Model and Financial Performance - DexCom's business model is highly lucrative, with hardware representing only 5% of revenue and disposable sensors accounting for 95%, supported by industry-leading retention rates [3] - Despite its strong business model, the stock has underperformed over the past five years, reflecting a negative 20% total return due to growing competition and market pressures [3] - The company faces challenges from Abbott's low-cost FreeStyle Libre platform and Medtronic's investments in next-generation CGM, alongside potential reduced demand from Type 2 patients due to the adoption of GLP-1 drugs [3] Group 3: Market Opportunities - CGM penetration remains low in key populations, including over 100 million Type 2 diabetics and prediabetics in the U.S., with expanding insurance coverage enhancing adoption potential [4] - International markets, such as Japan and Saudi Arabia, are underpenetrated, offering additional growth opportunities [4] - The entry into over-the-counter and wellness markets with Stelo may create new revenue streams for the company [4] Group 4: Investment Thesis - The combination of a high-margin, sticky business model, innovation leadership, and underpenetrated markets provides a compelling risk/reward profile for investors [4] - Previous bullish theses highlighted product innovation, Type 2 diabetes expansion, and user growth despite margin pressures, although the stock has depreciated about 6% since then due to competition and cost headwinds [5] - The current thesis emphasizes reimbursement gains and platform integration, while also acknowledging risks associated with GLP-1 drugs [5]